Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H2 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 44, 37, 1, 14, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 2 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology).

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

• A. Menarini Industrie Farmaceutiche Riunite Srl
• AbbVie Inc
• Actinium Pharmaceuticals Inc
• ADC Therapeutics SA
• Aduro BioTech Inc
• Affimed GmbH
• Agios Pharmaceuticals Inc
• AlfaSigma SpA
• Alissa Pharma
• Angiocrine Bioscience Inc
• Anhui Anke Biotechnology (Group) Co Ltd
• Apollomics Inc
• Astellas Pharma Inc
• AstraZeneca Plc
• Aurigene Discovery Technologies Ltd
• Avipep Pty Ltd
• BeiGene Ltd
• Biohaven Pharmaceutical Holding Company Ltd
• Bristol-Myers Squibb Co
• Carrick Therapeutics Ltd
• Catalent Inc
• Celgene Corp
• Cell Medica Ltd
• Celldex Therapeutics Inc
• Cellectar Biosciences Inc
• Cellectis SA
• Celleron Therapeutics Ltd
• Cellestia Biotech AG
• Cellular Biomedicine Group Inc
• Celularity Inc
• Checkmate Pharmaceuticals Inc
• Checkpoint Therapeutics Inc
• Chipscreen Biosciences Ltd
• Constellation Pharmaceuticals Inc
• CSL Ltd
• CStone Pharmaceuticals Co Ltd
• Curis Inc
• Eutilex Co Ltd
• F. Hoffmann-La Roche Ltd
• Faron Pharmaceuticals Oy
• Gibson Oncology LLC
• Harbin Gloria Pharmaceuticals Co Ltd
• Hebei Senlang Biotechnology Inc Ltd
• Helocyte Biosciences Inc
• HRAIN Biotechnology Co Ltd
• Immune Cell Inc
• Immunomedics Inc
• Incuron LLC
• Incyte Corp
• Inhibrx Inc
• Kite Pharma Inc
• Magenta Therapeutics Inc
• Marker Therapeutics Inc
• Merck & Co Inc
• Merck KGaA
• Millennium Pharmaceuticals Inc
• Miltenyi Biotec GmbH
• NantKwest Inc
• NBE-Therapeutics AG
• NewBio Therapeutics Inc
• Northlake International LLC
• OncoTartis Inc
• Protheragen Inc
• RAPT Therapeutics Inc
• Regeneron Pharmaceuticals Inc
• Rhizen Pharmaceuticals SA
• Rich Pharmaceuticals Inc
• Rizen (Suzhou) Biosciences Co Ltd
• Sanofi
• Seattle Genetics Inc
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
• Shanghai Junshi Bioscience Co Ltd
• Shanghai Pharmaceutical Group Co Ltd
• Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
• Shattuck Labs Inc
• Sichuan Kelun Pharmaceutical Co Ltd
• SpecificiT Pharma Inc
• Stemline Therapeutics Inc
• Syndax Pharmaceuticals Inc
• TaiGen Biotechnology Co Ltd
• Taiwan Liposome Co Ltd
• Trillium Therapeutics Inc
• Tyme Technologies Inc
• Wuhan Bio-Raid Biotechnology Co Ltd
• Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jb86i9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900